Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT06438705 Recruiting - Lung Cancer Clinical Trials

99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

Start date: February 1, 2024
Phase:
Study type: Observational

At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.

NCT ID: NCT06427954 Not yet recruiting - Lung Cancer Clinical Trials

Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer

THRIVE
Start date: September 2024
Phase: N/A
Study type: Interventional

Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer.

NCT ID: NCT06426628 Recruiting - Lung Cancer Clinical Trials

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

NIGHTINGALE
Start date: July 18, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: - Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? - Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer? Participants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.

NCT ID: NCT06424327 Recruiting - Lung Cancer Clinical Trials

A Registry for People With Lung Cancer

Start date: May 15, 2024
Phase:
Study type: Observational

Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

NCT ID: NCT06423690 Not yet recruiting - Lung Cancer Clinical Trials

First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection

NCT ID: NCT06423066 Not yet recruiting - Lung Cancer Clinical Trials

Developing a Machine Learning Model to Predict Pleural Adhesion Preoperatively Using Pleural Ultrasound

Start date: June 1, 2024
Phase:
Study type: Observational

This study aims to investigate the accuracy of using pleural ultrasound (USP) to identify pleural adhesions in patients who plan to receive video-assisted thoracoscopic surgery. It employs three-dimensional convolutional neural network (3D-CNN) technology to process USP-related images and video data for machine learning, and to establish a diagnostic model for identifying pleural adhesions using 3D-CNN-USP. The study will determine the sensitivity, specificity, positive predictive value, and negative predictive value of 3D-CNN-USP in identifying pleural adhesions. Additionally, it will explore the feasibility and effectiveness of using 3D-CNN-USP for preoperative identification of pleural adhesions in VATS, thereby supporting the implementation of day surgery in thoracic surgery and ultimately serving clinical practice.

NCT ID: NCT06421298 Recruiting - Lung Cancer Clinical Trials

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Start date: May 17, 2024
Phase: Phase 2
Study type: Interventional

The second-line treatment for patients who have progressed after first-line immune checkpoint inhibitor therapy, is chemotherapy based on docetaxel and other drugs. The treatment effect is limited. The median survival time of them are 6 months. So there is a huge unmet medical need. This study is a Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. 30 patients will be enrolled. The main endpoint is PFS,and the secondary endpoint are OS,DCR,DOR,ORR, and so on.

NCT ID: NCT06420206 Recruiting - Lung Cancer Clinical Trials

Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center

Start date: May 14, 2024
Phase: N/A
Study type: Interventional

To improve quality of life for participants with advanced cancer, support their families, and lower overall cost of care.

NCT ID: NCT06413212 Recruiting - Breast Cancer Clinical Trials

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing

Start date: August 4, 2023
Phase:
Study type: Observational

To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.

NCT ID: NCT06410716 Recruiting - Lung Cancer Clinical Trials

Comparing Valve-regulated Pleural Drainage to Traditional Closed Chest Tube Drainage

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

Thoracic drainage is an important adjunctive treatment following thoracic surgery, primarily aimed at removing postoperative blood, air, and exudate from the thoracic cavity. It helps maintain negative pressure in the thoracic cavity, promotes full lung expansion, and prevents pulmonary complications, especially atelectasis. Traditional closed thoracic drainage methods have many limitations. Dry valve-regulated pleural drainage system overcome these limitations. Preliminary studies have shown that they offer advantages such as high safety, ease of operation, and reduced nursing burden. The investigators plan to conduct a real-world randomized controlled study comparing the clinical efficacy of dry valve-regulated pleural drainage system with traditional water-sealed drainage systems, both of which are commonly used in clinical practice. The goal of this study is to provide solid evidence based on evidence-based medicine for the optimal practice of thoracic drainage, further optimize post-thoracic surgery drainage treatment protocols, enhance the quality and efficiency of patient care, and provide scientific evidence for the development or updating of relevant clinical guidelines.